Comparison of Alectinib/Crizotinib Data in First-Line Therapy in Patients with Anaplastic LymphomakinasePositive Nonsmall Cell Lung Carcinoma with Poor Prognostic Features for Alectinib

• Nuran Katgı,
• Pınar Çimen,
• Murat Akyol,
• Pınar Gürsoy,
• Nurşin Agüloğlu

Affiliations

Nuran Katgı

Pınar Çimen

Department of Pulmonology, Dr. Suat Seren Chest Diseases and Surgery Training and Research Hospital, İzmir, Turkey

Murat Akyol

Department of Medical Oncology, Bakırçay University, İzmir, Turkey

Pınar Gürsoy

Department of Medical Oncology, Ege University, İzmir, Turkey

Nurşin Agüloğlu

Department of Nuclear Medicine, Dr. Suat Seren Chest Diseases and Surgery Training and Research Hospital, İzmir, Turkey